Skip to main content
. 2015 Feb 25;67(3):668–677. doi: 10.1002/art.38973

Figure 1.

Figure 1

A, RAPID-axSpA trial design: certolizumab pegol (CZP) in active axial spondyloarthritis. B, Patient disposition in the RAPID-axSpA trial to week 96. * All patients received allocated treatment. † One patient did not enroll in the dose-blind trial period. Values are the number (%) of patients. Q2W = every 2 weeks; Q4W = every 4 weeks; ASAS20 = Assessment of SpondyloArthritis international Society criteria for 20% improvement in disease activity; PBO = placebo.